Dimerix Ltd., of Melbourne, Australia, said research on CRISPR technology has been published in Scientific Reports. A research team at the Harry Perkins Institute of Medical Research has developed tools for studying functional receptor interactions in real time, which enabled them to validate the relevance of the Dimerix receptor-heteromer investigation technology (Receptor-HIT) platform technology to monitor receptor complexes by labeling and monitoring endogenous receptors with tags for bioluminescence resonance energy transfer (BRET).